Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys.

Aptamers are oligonucleotide ligands selected, in vitro, to bind a specified target protein. The first aptamer to reach human clinical testing is NX1838, a polyethylene glycol conjugated aptamer that inhibits vascular endothelial growth factor. This paper describes the validation of a high-performance liquid chromatographic anion-exchange method for the determination of NX1838 in plasma. Measurements of intact NX1838 had a coefficient of variation of less than 8% and an accuracy between 107% and 115%. The assay was utilized to determine NX1838 plasma pharmacokinetics in rhesus monkeys following a single 1 mg/kg intravenous or subcutaneous dose. Following intravenous administration, the maximum achieved plasma concentration was 25.5 microg/ml with a terminal half-life of 9.3 h and clearance rate of 6.2 ml/h. After subcutaneous administration, the fraction of the dose absorbed into the plasma compartment was 0.78 with a time to peak concentration (4.9 microg/ml) of 8 to 12 h.

[1]  F. Eckstein,et al.  Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. , 1991, Science.

[2]  D. Gospodarowicz,et al.  Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells. , 1989, The EMBO journal.

[3]  S. Kondo,et al.  Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. , 1993, Biochemical and biophysical research communications.

[4]  M. Klagsbrun,et al.  Regulators of angiogenesis. , 1991, Annual review of physiology.

[5]  B. Keyt,et al.  A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasma. , 1998, Journal of immunological methods.

[6]  L. Gold,et al.  Oligonucleotides as Research, Diagnostic, and Therapeutic Agents(*) , 1995, The Journal of Biological Chemistry.

[7]  Joan W. Miller,et al.  Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. , 1996, Investigative ophthalmology & visual science.

[8]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[9]  N. Janjić,et al.  Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.

[10]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[11]  P. D. Cook,et al.  Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. , 1995, Nucleic acids research.

[12]  A. Ellington,et al.  RNA Selection: Aptamers achieve the desired recognition , 1994, Current Biology.

[13]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[14]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[15]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[16]  J. Winer,et al.  The vascular endothelial growth factor family of polypeptides , 1991, Journal of cellular biochemistry.

[17]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[18]  T. V. Berkel,et al.  Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution , 1991 .

[19]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[20]  Directed evolution of nucleic acids by independent replication and selection. , 1990, Science.

[21]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[22]  C. Vargeese,et al.  Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. , 1995, Biochemistry.

[23]  Joan W. Miller,et al.  Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. , 1994, American journal of ophthalmology.

[24]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[25]  T. Zhang,et al.  Liposome-anchored vascular endothelial growth factor aptamers. , 1998, Bioconjugate chemistry.